PREPARED BY: DATE PREPARED: PHONE: Nikki Swope February 22, 2024 402-471-0042 **LB 1232**

Revision: 00

FISCAL NOTE

LEGISLATIVE FISCAL ANALYST ESTIMATE

ESTIMATE OF FISCAL IMPACT – STATE AGENCIES (See narrative for political subdivision estimates)						
	FY 202	FY 20	25-26			
	EXPENDITURES	REVENUE	EXPENDITURES	REVENUE		
GENERAL FUNDS						
CASH FUNDS						
FEDERAL FUNDS						
OTHER FUNDS						
TOTAL FUNDS	See below		See below			

Any Fiscal Notes received from state agencies and political subdivisions are attached following the Legislative Fiscal Analyst Estimate.

LB 1232 would prohibit Pharmacy Benefit Managers (PBM) from reimbursing any pharmacist or pharmacy for any drug at a rate lower than the cost required to dispense the drug.

The State of Nebraska and the University System contract with a vendor for pharmacy benefits for employee coverage. The vendor contracts with a PBM to manage prescriptions and costs. However, the rates that pharmacies pay for prescription drugs and whether pharmacies have been reimbursed below acquisition costs for prescription drugs are unknown.

Both the State of Nebraska and the University System would be required to renegotiate a new contract for pharmacy benefits plans with the passage of the bill. It is probable that the cost of the new contracts would require increased premiums but the costs are indeterminable. The University System indicated that that a new contract would have to be negotiated but did not foresee a fiscal impact. The State of Nebraska anticipates that while the increases in premium costs are unknown, they would have a significant fiscal impact.

The proposal to disallow the reimbursement of drugs lower than the cost required to dispense the drugs also creates complexities for Medicaid plans and Managed Care Organizations (MCOs). This would lead to Medicaid paying each pharmacy their individual operational cost. The fiscal impact is difficult to quantify as these costs are unknown. The Department of Health and Human Services estimates a \$5,000,000 cost annually in state funds for the increased pharmacy benefit payments for Medicaid, CHIP, and Medicaid Expansion.

The Department of Insurance (DOI) is responsible for enforcement of the requirements of the PBM Act. To enforce this provision, the Department would need additional staff to review complaints and document the pharmacy's actual cost to dispense drugs and compare to the PBM's reimbursement rate.

The DOI would need to employ a FTE Market Conduct Examiner to fulfill this obligation. The cost for the additional staff would be \$83,843 in FY 2024-25 and \$86,457 in FY 2025-26.

ADMIN	ISTRATIVE SERVICE	S STATE BUDGET DIVISION: REVIE	W OF AGENCY & POLT. SUB. RESPONSE		
LB: 1232	AM:	AGENCY/POLT. SUB: Departme	nt of Health and Human Services (DHHS)		
REVIEWED B	3Y: Ryan Walton	DATE: 2/23/2024	PHONE: (402) 471-4174		
COMMENTS: The DHHS' assessment of fiscal impact from LB 1232 appears reasonable.					

ADMIN	ISTRATIVE SERVICE	S STATE BUDGET DIVISION: REVIE	W OF AGENCY & POLT. SUB. RESPONSE			
LB: 1232	AM:	AGENCY/POLT. SUB: Departme	nt of Insurance			
REVIEWED B	BY: Ryan Walton	DATE: 2/22/2024	PHONE: (402) 471-4174			
COMMENTS: The Department of Insurance's assessment of fiscal impact from LB 1232 appears reasonable.						

ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE					
LB: 1232	AM:	1391	AGENCY/POLT. SUB: Uni	versity of Nebraska Systems	
REVIEWED BY:	Ryan Walto	on	DATE: 1/26/2024	PHONE: (402) 471-4174	
COMMENTS: The University of Nebraska Systems assessment of no fiscal impact from LB 1232 appears reasonable.					

ADMINI	STRATIVE SERVICE	S STATE BUDGET DIVISION: REVIE	W OF AGENCY & POLT. SUB. RESPONSE		
LB: 1232	AM:	AGENCY/POLT. SUB: Departme	ent of Administrative Services (DAS)		
REVIEWED BY: Ryan Walton DATE: 1/26/2024 PHONE: (402) 471-4174					
COMMENTS: The DAS assessment of indeterminate fiscal impact from LB 1232 appears reasonable.					

LB ⁽¹⁾ 1232					FISCAL NOTE
State Agency OR Po	olitical Subdivision Name: ⁽²⁾	Department of Adr -Employee Wellne		vices (DAS)	
Prepared by: (3)	Jennifer Norris	Date Prepared: (4)	1/18/2024	Phone: (5)	402/480-9728
	ESTIMATE PROVI	DED BY STATE AGEN	ICY OR POLITICA	L SUBDIVIS	ION
	TOY (2024 25		EV 2027	20
	EXPENDITURES	<u>2024-25</u> <u>REVENUE</u>	EXPENDIT	<u>FY 2025-</u> <u>URES</u>	<u>REVENUE</u>
GENERAL FUNI	os				
CASH FUNDS					
FEDERAL FUND	os				
REVOLVING FUN	DS				
TOTAL FUNDS					

Explanation of Estimate:

LB 1232 proposes to prohibit a pharmacy benefit manager to not reimburse any pharmacist or pharmacy for any drug at a rate lower than the cost required to dispense the drug.

LB 1232 would cause the current health and pharmacy contract to be renegotiated due to the unknown cost as a pharmacy may request reimbursement of the cost to purchase and to dispense drugs without verification of best and lowest cost being reported.

The State of Nebraska contracts with a vendor for health and pharmacy coverage. The vendor contracts with a Pharmacy Benefits Manager (PBM) to manage prescriptions and costs. Neither the vendor nor the PBM have information on what rate a pharmacy pays for a prescription drug. Neither the vendor nor the PBM know if a pharmacy has been reimbursed below acquisition cost. Currently the vendor for the State of Nebraska health plans allows a pharmacy to submit an appeal if the Maximum Allowable Cost (MAC) reimbursement or the list pricing is below the pharmacy's acquisition cost. With this appeal process, the PBM will review the MAC list pricing to confirm whether the MAC list price is appropriate or should be adjusted for the pharmacy. This appeal process protects the State of Nebraska health plans from reimbursing pharmacies at an unreasonably high acquisition cost.

Passage of LB 1232 would result in an unknown increase in costs to the state due to the renegotiation of the current contract to reimburse for an unknown cost to a pharmacy which has determined the price of prescriptions as their rates of acquisition and their cost of dispensation. This circumvents the vendor's ability to lower pharmacy costs.

The State's health plans are self-insured. Increased costs will require premium increases. The state of Nebraska covers 79% of the cost of health and pharmacy premiums for state employees.

LB 1232, as written, has an unknown but relevant fiscal impact to the State of Nebraska health plans.

BREAKD	OWN BY MAJ	OR OBJECTS O	F EXPENDITURE		
Personal Services:					
	NUMBER OF	POSITIONS	2024-25	2025-26	
POSITION TITLE	<u>24-25</u>	<u>25-26</u>	EXPENDITURES	EXPENDITURES	
Benefits	•				
Operating					
Travel					
Capital outlay					
Aid					
Capital improvements					
TOTAL					

	ESTIMATE PROVIDED BY STATE AGENCY OR POLITICAL SUBDIVISION						
State Agency or Political Subdivision Name:(2) Department of Health and Human Services							
Prepared by: (3) John Meals	Date Prepared 2-22-2024 Phone: (5) 471-67						
	FY 2024	FY 2025	<u>-2026</u>				
_	EXPENDITURES	REVENUE	EXPENDITURES	REVENUE			
GENERAL FUNDS							
CASH FUNDS							
FEDERAL FUNDS							
OTHER FUNDS							
TOTAL FUNDS	See Below		See Below				
-							
Return by date specified or 72 h	nours prior to public hearing,	whichever is earlier.					

Explanation of Estimate:

LB1232 changes requirements for the Pharmacy Benefit Manager (PBM) Licensure and Regulation Act by prohibiting a pharmacy benefit manager from reimbursing a pharmacist or pharmacy for any drug lower than the cost to dispense that drug.

Federal law allows Medicaid plans and Managed Care Organizations (MCOs) multiple options to utilize in determining reimbursement to pharmacies for medications dispensed to Medicaid recipients. Each pharmacy negotiates drug-specific reimbursement rates with a PBM and uses maximum allowable cost (MAC) and national average drug acquisition cost (NADAC) methodology for pricing calculation.

The bill proposal for not reimbursing drugs lower than the cost required to dispense the drugs has operational complexities. Pharmacies often receive discounts or rebates on subsequent months or quarter invoices based upon the previous month or quartet dispensed volume, which are not reflected in their cost submitted for reimbursement. This bill would require a mechanism for each pharmacy to submit their acquisition cost for each medication to the PBM, which is unclear if it applies only to medication cost or the entire cost to dispense. This would lead to Medicaid paying each pharmacy their individual operational cost.

A similar bill (LB778) was introduced in the 2023 session. The program aid cost related to pharmacy is very difficult to quantify due to individual pharmacies contracting with drug wholesalers for the purchase of medications. Drug wholesalers set the acquisition price for individual pharmacies. The department's best estimate is \$5 million per state fiscal year in total funds. The majority of the costs would be increased for MCO pharmacy payments. These would be Medicaid, CHIP, and Medicaid Expansion expenditures and eligible for applicable FMAP rates.

MAJOR OBJEC	TS OF EXPEND	TURE		
PERSONAL SERVICES:				
DOCUTION TITLE		POSITIONS	2024-2025	2025-2026
POSITION TITLE	24-25	25-26	EXPENDITURES	EXPENDITURES
Benefits				
Operating				
Travel				
Capital Outlay		_		
Aid				
Capital Improvements		_		
TOTAL				

Please complete <u>A</u>	<u>LL</u> (5) blanks in the first thro	ee lines.			2024
LB ⁽¹⁾ 1232				1	FISCAL NOTE
State Agency OR Po	olitical Subdivision Name: (2)	Department of Ins	urance		
Prepared by: ⁽³⁾	Jordan Blades	Date Prepared: (4)	2/14/2024	Phone: (5)	402-471-4638
	ESTIMATE PROVI	DED BY STATE AGEN	CY OR POLITIC	CAL SUBDIVIS	ION
	·	<u>2024-25</u>		FY 2025	
	EXPENDITURES	<u>REVENUE</u>	EXPENDI	TURES	<u>REVENUE</u>
GENERAL FUND	os		<u> </u>		
CASH FUNDS	83,843		86,4	57	
FEDERAL FUND	s		. <u> </u>		
OTHER FUNDS			. <u> </u>		
TOTAL FUNDS	83,843		86,4	57	
Explanation of Est	timate:				
Pharmacy Benef	amend the Pharmacy Be fit Manager's (PBM's) fro quired to dispense the dr	om reimbursing any pl	•	`	, .
enforce this prov	of Insurance is responsition in the event of a cospense, which is not limit ement rate.	emplaint, the Departm	ent would need	to document	the pharmacy's
The Department	would need to hire a ful	I time Market Conduc	t Examiner to re	eview complair	nts arising from LB

1232.

Administrative actions to enforce the Act must be handled by an attorney within the Department. If the number of administrative actions exceeds the Department's current estimate, additional staff may be needed in the future.

Personal Services:	EAKDOWN BY MA.				
POSITION TITLE	NUMBER OI <u>24-25</u>	F POSITIONS <u>25-26</u>	2024-25 <u>EXPENDITURES</u>	2025-26 <u>EXPENDITURES</u>	
Market Conduct Examiner II 1		1	49,875	51,371	
Benefits			31,466	32,410	
Operating			2,502	2,676	
Travel					
Capital outlay					
Aid					
Capital improvements					
TOTAL			83,843	86,457	

LB (1) 1232 Prohibit certain actions under the Pharmacy Benefit Manager Licensure FISCAL NOTE and Regulation Act

State Agency OR Political Subdivision Name: University of Nebraska System								
Prepared by: ⁽³⁾ Chris Kabourek		Date Prepared: (4)	01/24/2024	Phone: ⁽⁵⁾	(402) 472-7102			
ESTIMATE PROVIDED BY STATE AGENCY OR POLITICAL SUBDIVISION								
	FY	2024 - 25		FY 2025 - 26				
GENERAL FUNDS	EXPENDITURES 0.00	REVENUE 0.00	EXPENDITU 0.00		0.00			
CASH FUNDS	0.00	0.00	0.00	<u>o_</u>	0.00			
FEDERAL FUNDS	0.00	0.00	0.00	<u>) </u>	0.00			
OTHER FUNDS	0.00	0.00	0.00	<u>) </u>	0.00			
TOTAL FUNDS	0.00	0.00	0.00	<u>) </u>	0.00			
Explanation of Estimate:								

No Fiscal Impact.

If LB 1232 were to pass and become law we would work with our pharmacy benefits manager (PBM) to make sure we comply with the law.

BREAKDOWN BY MAJOR OBJECTS OF EXPENDITURE

reisonal Services.				
POSITION TITLE	NUMBER OF POSITIONS 24 - 25 25 - 26		2024 - 25 EXPENDITURES	2025 - 26 EXPENDITURES
<u> </u>	0	0		
_	0	0		
Benefits				
Operating				
Travel				
Capital outlay				
Aid				
Capital improvements			_	
TOTAL				